Alkermes is handed a CRL for ‘3831, marking another setback on the R&D front

Alkermes is handed a CRL for ‘3831, marking another setback on the R&D front

Source: 
Endpoints
snippet: 

Alkermes $ALKS is going to have to wait some more before launching its anti-psychotic combo drug ALKS-3831. The FDA has handed the biotech a CRL, rejecting the application in the company’s latest setback in R&D.